Register for email alerts and news feeds:
This journal | BMJ Group
rss
Thorax 2003;58:284-285; doi:10.1136/thorax.58.4.284
Copyright © 2003 BMJ Publishing Group Ltd & British Thoracic Society.
Thorax 2003;58:284-285
© 2003 BMJ Publishing Group & British Thoracic Society

EDITORIAL

Childhood asthma

Second line treatment for severe acute childhood asthma

M South

M South, Director, Department of General Medicine, Royal Children's Hospital; Associate Professor and Deputy Head, Department of Paediatrics, University of Melbourne; Research Fellow, Murdoch Children's Research Institute, Melbourne, Australia

Correspondence to:
Correspondence to:
Dr M South, Royal Children's Hospital, Parkville, Victoria 3052, Australia;
mike.south@rch.org.au


The choice of treatment for a child with severe acute asthma unresponsive to high dose inhaled bronchodilators and oral or intravenous corticosteroids is still the subject of debate. Although both salbutamol and aminophylline have been around for a long time and have been the subject of many studies, it is still not possible unreservedly to recommend one of these agents over the other as second line treatment.

Keywords: asthma; children; second line treatment

The first 150 words of the full text of this article appear below.

Most physicians would agree that first line treatment for an acute exacerbation of childhood asthma should be the administration of high dose inhaled bronchodilators1 and corticosteroids administered either orally or intravenously,2 but when a child with severe acute asthma is unresponsive to such treatment—what should come next? This is an important question that is faced by doctors every day in emergency departments, paediatric wards, and intensive care units the world over. Most commonly, physicians will reach next for intravenous salbutamol or intravenous aminophylline, although some will consider other treatments.

Salbutamol and aminophylline have been shown to be individually better than placebo in severe acute asthma.3,4 Although a recent Cochrane systematic review appeared to cast doubt on this statement for salbutamol,5 many suspect that this is a flaw caused by the inclusion of several very weak early studies of salbutamol in the analysis. A large study of aminophylline6 and . . . [Full text of this article]


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Relevant Article

Airwaves
Wisia Wedzicha
Thorax 2003 58: 283. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

  • Babl, F E, Sheriff, N, Borland, M, Acworth, J, Neutze, J, Krieser, D, Ngo, P, Schutz, J, Thomson, F, Cotterell, E, Jamison, S, Francis, P (2008). Paediatric acute asthma management in Australia and New Zealand: practice patterns in the context of clinical practice guidelines. Arch. Dis. Child. 93: 307-312 [Abstract] [Full Text]  
  • Grigg, J (2004). Management of paediatric asthma. Postgrad. Med. J. 80: 535-540 [Abstract] [Full Text]  
  • Vijayadeva, S, South, M (2004). Treatment of severe acute childhood asthma. Thorax 59: 450-451 [Full Text]  

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Chest Medicine Jobs

Chest Medicine Jobs